B.Riley analyst Kalpit Patel reiterated a Buy rating and $155.00 price target on Kymera Therapeutics (NASDAQ: KYMR).The analyst comments "We ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

Citi Opens 90-Day Upside Catalyst Watch on Kymera Therapeutics (KYMR)October 5, 2026 5:24 AM